Self-copying RNA Vaccine Approval Explained
The approval of yet another RNA-based vaccine might not seem momentous, wrote Elie Dolgin in an article published by the journal Nature.
But the endorsement last week by Japanese authorities of a jab against the SARS-CoV-2 coronavirus constructed using a form of RNA that can make copies of itself inside cells — the first 'self-amplifying' RNA granted full regulatory approval anywhere in the world — marks a pivotal advance.
The December 6, 2023, article is posted at this link.
In late November 2023, CSL and Arcturus Therapeutics announced that Japan's Ministry of Health, Labor, and Welfare approved ARCT-154, a self-amplifying Messenger RNA COVID-19 vaccine for initial vaccination and booster for adults 18 years and older.
Our Trust Standards: Medical Advisory Committee
